{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:11:35Z","timestamp":1795011095874,"version":"4.9.1"},"reference-count":298,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL150266"],"award-info":[{"award-number":["R01HL150266"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL152090"],"award-info":[{"award-number":["R01HL152090"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","id":[{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown significant utility in the treatment of multiple hematological malignancies and solid tumors, including chronic myelogenous leukemia, non-small cell lung cancers, gastrointestinal stromal tumors, and HER2-positive breast cancers. Given their widespread applications, an increasing frequency of TKI-induced adverse effects has been reported. Although TKIs are known to affect multiple organs in the body including the lungs, liver, gastrointestinal tract, kidneys, thyroid, blood, and skin, cardiac involvement accounts for some of the most serious complications. The most frequently reported cardiovascular side effects range from hypertension, atrial fibrillation, reduced cardiac function, and heart failure to sudden death. The potential mechanisms of these side effects are unclear, leading to critical knowledge gaps in the development of effective therapy and treatment guidelines. There are limited data to infer the best clinical approaches for the early detection and therapeutic modulation of TKI-induced side effects, and universal consensus regarding various management guidelines is yet to be reached. In this\n                    <jats:italic>state-of-the-art<\/jats:italic>\n                    review, we examine multiple pre-clinical and clinical studies and curate evidence on the pathophysiology, mechanisms, and clinical management of these adverse reactions. We expect that this review will provide researchers and allied healthcare providers with the most up-to-date information on the pathophysiology, natural history, risk stratification, and management of emerging TKI-induced side effects in cancer patients.\n                  <\/jats:p>","DOI":"10.1038\/s41392-023-01469-6","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T20:02:04Z","timestamp":1688673724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":522,"title":["Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8167-0369","authenticated-orcid":false,"given":"Sunitha","family":"Shyam Sunder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh C.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraswati","family":"Pokharel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"1469_CR1","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1469_CR2","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/sctm.18-0279","volume":"8","author":"P Nair","year":"2019","unstructured":"Nair, P., Prado, M., Perea-Gil, I. & Karakikes, I. Concise review: precision matchmaking: induced pluripotent stem cells meet cardio-oncology. Stem Cells Transl. Med. 8, 758\u2013767 (2019).","journal-title":"Stem Cells Transl. Med."},{"key":"1469_CR3","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J. & Larkin, J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 19, e447\u2013e458 (2018).","journal-title":"Lancet Oncol."},{"key":"1469_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","volume":"2","author":"F Broekman","year":"2011","unstructured":"Broekman, F., Giovannetti, E. & Peters, G. J. Tyrosine kinase inhibitors: multi-targeted or single-targeted? World J. Clin. Oncol. 2, 80 (2011).","journal-title":"World J. Clin. Oncol."},{"key":"1469_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/apjon.apjon_79_17","volume":"5","author":"G Wilkes","year":"2018","unstructured":"Wilkes, G. Targeted therapy: attacking cancer with molecular and immunological targeted agents. Asia-Pac. J. Oncol. Nurs. 5, 137\u2013155 (2018).","journal-title":"Asia-Pac. J. Oncol. Nurs."},{"key":"1469_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu, F. et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct. Target. Ther. 6, 1\u201335 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1469_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong, L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct. Target. Ther. 6, 1\u201348 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1469_CR8","doi-asserted-by":"crossref","unstructured":"Grossman, M. & Adler, E. Protein Kinase Inhibitors\u2014Selectivity or Toxicity? (IntechOpen, 2021).","DOI":"10.5772\/intechopen.98640"},{"key":"1469_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1021\/cb500886n","volume":"10","author":"O Hantschel","year":"2015","unstructured":"Hantschel, O. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors. ACS Chem. Biol. 10, 234\u2013245 (2015).","journal-title":"ACS Chem. Biol."},{"key":"1469_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore, S. D., Kohnken, R. A., Peters, M. F. & Kolaja, K. L. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem. Res. Toxicol. 33, 125\u2013136 (2020).","journal-title":"Chem. Res. Toxicol."},{"key":"1469_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3892\/mco.2016.800","volume":"4","author":"Z CHEN","year":"2016","unstructured":"CHEN, Z. & AI, D. Cardiotoxicity associated with targeted cancer therapies. Mol. Clin. Oncol. 4, 675\u2013681 (2016).","journal-title":"Mol. Clin. Oncol."},{"key":"1469_CR12","doi-asserted-by":"publisher","first-page":"17295","DOI":"10.1021\/acsomega.8b02998","volume":"3","author":"F Miljkovi\u0107","year":"2018","unstructured":"Miljkovi\u0107, F. & Bajorath, J. Computational analysis of kinase inhibitors identifies promiscuity cliffs across the human kinome. ACS Omega 3, 17295\u201317308 (2018).","journal-title":"ACS Omega"},{"key":"1469_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","volume":"36","author":"DR Shah","year":"2013","unstructured":"Shah, D. R., Shah, R. R. & Morganroth, J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 36, 413\u2013426 (2013).","journal-title":"Drug Saf."},{"key":"1469_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","volume":"78","author":"F Petrelli","year":"2012","unstructured":"Petrelli, F., Borgonovo, K., Cabiddu, M., Lonati, V. & Barni, S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 78, 8\u201315 (2012).","journal-title":"Lung Cancer"},{"key":"1469_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/leu.2010.215","volume":"25","author":"E Jabbour","year":"2011","unstructured":"Jabbour, E., Deininger, M. & Hochhaus, A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25, 201\u2013210 (2011).","journal-title":"Leukemia"},{"key":"1469_CR16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.5498\/wjp.v11.i10.736","volume":"11","author":"X-Q Li","year":"2021","unstructured":"Li, X.-Q., Tang, X.-R. & Li, L.-L. Antipsychotics cardiotoxicity: What\u2019s known and what\u2019s next. World J. Psychiatry 11, 736\u2013753 (2021).","journal-title":"World J. Psychiatry"},{"key":"1469_CR17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon, A. R. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur. J. Heart Fail. 22, 1945\u20131960 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1469_CR18","first-page":"100144","volume":"17","author":"JA Gomez","year":"2022","unstructured":"Gomez, J. A. Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies. Am. Hear. J. Cardiol. Res. Pr. 17, 100144 (2022).","journal-title":"Am. Hear. J. Cardiol. Res. Pr."},{"key":"1469_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.cels.2019.03.009","volume":"8","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Adaptation of human iPSC-derived cardiomyocytes to tyrosine kinase inhibitors reduces acute cardiotoxicity via metabolic reprogramming. Cell Syst. 8, 412\u2013426.e7 (2019).","journal-title":"Cell Syst."},{"key":"1469_CR20","first-page":"277","volume":"3","author":"T Eschenhagen","year":"2018","unstructured":"Eschenhagen, T. Exaggerated cardiotoxicity of sunitinib in stressed 3-dimensional heart muscles. JACC: Basic Transl. Sci. 3, 277\u2013279 (2018).","journal-title":"JACC: Basic Transl. Sci."},{"key":"1469_CR21","first-page":"12","volume":"11","author":"B Tomaszewska","year":"2021","unstructured":"Tomaszewska, B., Muzolf, M., Grabysa, R. & Bodnar, L. Cardiotoxicity of antiangiogenic drugs: causes and mechanisms. Oncol. Rev. 11, 12\u201318 (2021).","journal-title":"Oncol. Rev."},{"key":"1469_CR22","doi-asserted-by":"crossref","first-page":"117954681986644","DOI":"10.1177\/1179546819866445","volume":"13","author":"IE Perez","year":"2019","unstructured":"Perez, I. E., Taveras Alam, S., Hernandez, G. A. & Sancassani, R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin. Med. Insights: Cardiol. 13, 1179546819866445 (2019).","journal-title":"Clin. Med. Insights: Cardiol."},{"key":"1469_CR23","doi-asserted-by":"publisher","first-page":"H891","DOI":"10.1152\/ajpheart.00259.2019","volume":"317","author":"PK Mishra","year":"2019","unstructured":"Mishra, P. K. et al. Guidelines for evaluating myocardial cell death. Am. J. Physiol. Heart Circ. Physiol. 317, H891 (2019).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1469_CR24","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3390\/genes13122183","volume":"13","author":"S Nishihara","year":"2022","unstructured":"Nishihara, S. et al. Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer. Genes 13, 2183 (2022).","journal-title":"Genes"},{"key":"1469_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04740-w","volume":"13","author":"AV Jacobsen","year":"2022","unstructured":"Jacobsen, A. V. et al. The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL. Cell Death Dis. 13, 291 (2022).","journal-title":"Cell Death Dis."},{"key":"1469_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/CS20200305","volume":"135","author":"SJH Dobbin","year":"2021","unstructured":"Dobbin, S. J. H., Petrie, M. C., Myles, R. C., Touyz, R. M. & Lang, N. N. Cardiotoxic effects of angiogenesis inhibitors. Clin. Sci. 135, 71\u2013100 (2021).","journal-title":"Clin. Sci."},{"key":"1469_CR27","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117, J. et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 22, 1504\u20131524 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1469_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano, G. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 31, 171\u2013190 (2020).","journal-title":"Ann. Oncol."},{"key":"1469_CR29","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","volume":"133","author":"J Herrmann","year":"2016","unstructured":"Herrmann, J. et al. Vascular toxicities of cancer therapies: the old and the new\u2014an evolving avenue. Circulation 133, 1272\u20131289 (2016).","journal-title":"Circulation"},{"key":"1469_CR30","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer, M. S. & Lippman, S. M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23, 2900\u20132902 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1469_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","volume":"31","author":"SM Ewer","year":"2008","unstructured":"Ewer, S. M. & Ewer, M. S. Cardiotoxicity profile of trastuzumab. Drug Saf. 31, 459\u2013467 (2008).","journal-title":"Drug Saf."},{"key":"1469_CR32","first-page":"HS24","volume":"42","author":"SA Thomas","year":"2017","unstructured":"Thomas, S. A. Chemotherapy agents that cause cardiotoxicity. U. S. Pharm. 42, HS24\u2013HS33 (2017).","journal-title":"U. S. Pharm."},{"key":"1469_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova, M. & Raymond Russell, I. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 7, 214 (2011).","journal-title":"Curr. Cardiol. Rev."},{"key":"1469_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","volume":"88","author":"MR Bristow","year":"1978","unstructured":"Bristow, M. R., Mason, J. W., Billingham, M. E. & Daniels, J. R. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann. Intern. Med. 88, 168\u2013175 (1978).","journal-title":"Ann. Intern. Med."},{"key":"1469_CR35","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1007\/s12032-010-9717-7","volume":"28","author":"XL Du","year":"2011","unstructured":"Du, X. L., Xia, R., Burau, K. & Liu, C. C. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med. Oncol. 28, S80\u2013S90 (2011).","journal-title":"Med. Oncol."},{"key":"1469_CR36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","volume":"70","author":"RM Touyz","year":"2017","unstructured":"Touyz, R. M., Lang, N. N., Herrmann, J., Van Den Meiracker, A. H. & Danser, A. H. J. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension 70, 220\u2013226 (2017).","journal-title":"Hypertension"},{"key":"1469_CR37","first-page":"397","volume":"24","author":"G Aslan","year":"2020","unstructured":"Aslan, G. et al. Evaluation of serum platelet-derived growth factor receptor-\u00df and brain-derived neurotrophic factor levels in microvascular angina. Anatol. J. Cardiol. 24, 397 (2020).","journal-title":"Anatol. J. Cardiol."},{"key":"1469_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-017-0044-8","volume":"2","author":"RM Touyz","year":"2018","unstructured":"Touyz, R. M. & Herrmann, J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis. Oncol. 2, 1\u201311 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"1469_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-017-0024-8","volume":"3","author":"D Pinkhas","year":"2017","unstructured":"Pinkhas, D., Ho, T. & Smith, S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardio-Oncol. 3, 5 (2017).","journal-title":"Cardio-Oncol."},{"key":"1469_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphys.2018.00167","volume":"9","author":"G Varricchi","year":"2018","unstructured":"Varricchi, G. et al. Antineoplastic drug-induced cardiotoxicity: a redox perspective. Front. Physiol. 9, 167 (2018).","journal-title":"Front. Physiol."},{"key":"1469_CR41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10549-017-4460-9","volume":"166","author":"HD Choi","year":"2017","unstructured":"Choi, H. D. & Chang, M. J. Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. Breast Cancer Res. Treat. 166, 927\u2013936 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"1469_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand, K., Ensor, J., Trachtenberg, B. & Bernicker, E. H. Osimertinib-Induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC CardioOncol. 1, 172\u2013178 (2019).","journal-title":"JACC CardioOncol."},{"key":"1469_CR43","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-018-0916-4","volume":"78","author":"A D\u00edaz-Serrano","year":"2018","unstructured":"D\u00edaz-Serrano, A., Gella, P., Jim\u00e9nez, E., Zugazagoitia, J. & Paz-Ares Rodr\u00edguez, L. Targeting EGFR in lung cancer: current standards and developments. Drugs 78, 893\u2013911 (2018).","journal-title":"Drugs"},{"key":"1469_CR44","doi-asserted-by":"publisher","first-page":"118493","DOI":"10.1016\/j.bbamcr.2019.06.007","volume":"1867","author":"M Li","year":"2020","unstructured":"Li, M., Russo, M., Pirozzi, F., Tocchetti, C. G. & Ghigo, A. Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118493 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"1469_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/OP.20.00924","volume":"17","author":"JR Stone","year":"2021","unstructured":"Stone, J. R., Kanneganti, R., Abbasi, M. & Akhtari, M. Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol. Pract. 17, 228\u2013236 (2021).","journal-title":"JCO Oncol. Pract."},{"key":"1469_CR46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3389\/fphar.2020.00891","volume":"11","author":"Y Jin","year":"2020","unstructured":"Jin, Y. et al. A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors. Front. Pharmacol. 11, 891 (2020).","journal-title":"Front. Pharmacol."},{"key":"1469_CR47","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","volume":"168","author":"S Winnik","year":"2013","unstructured":"Winnik, S. et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis\u2014implications for cardiovascular safety. Int. J. Cardiol. 168, 2453\u20132461 (2013).","journal-title":"Int. J. Cardiol."},{"key":"1469_CR48","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1097\/HJH.0000000000000662","volume":"33","author":"AMJ Thijs","year":"2015","unstructured":"Thijs, A. M. J. et al. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension. J. Hypertens. 33, 2075\u20132082 (2015).","journal-title":"J. Hypertens."},{"key":"1469_CR49","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang, H. M., Moudgil, R., Scarabelli, T., Okwuosa, T. M. & Yeh, E. T. H. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J. Am. Coll. Cardiol. 70, 2536\u20132551 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1469_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-75","volume":"9","author":"JR Sierra","year":"2010","unstructured":"Sierra, J. R., Cepero, V. & Giordano, S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75 (2010).","journal-title":"Mol. Cancer"},{"key":"1469_CR51","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/bjc.2014.564","volume":"112","author":"P Ghatalia","year":"2015","unstructured":"Ghatalia, P., Je, Y., Kaymakcalan, M. D., Sonpavde, G. & Choueiri, T. K. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br. J. Cancer 112, 296\u2013305 (2015).","journal-title":"Br. J. Cancer"},{"key":"1469_CR52","doi-asserted-by":"crossref","unstructured":"Buza, V., Rajagopalan, B. & Curtis, A. B. Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ. Arrhythm. Electrophysiol. 10, e005443 (2017).","DOI":"10.1161\/CIRCEP.117.005443"},{"key":"1469_CR53","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00280-010-1372-3","volume":"67","author":"AW Tolcher","year":"2011","unstructured":"Tolcher, A. W. et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother. Pharmacol. 67, 751\u2013764 (2011).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1469_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-019-0657-y","volume":"20","author":"S Chandrasekhar","year":"2019","unstructured":"Chandrasekhar, S. & Fradley, M. G. QT interval prolongation associated with cytotoxic and targeted cancer therapeutics. Curr. Treat. Options Oncol. 20, 1\u201317 (2019).","journal-title":"Curr. Treat. Options Oncol."},{"key":"1469_CR55","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","volume":"77","author":"VU Rao","year":"2021","unstructured":"Rao, V. U. et al. Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review. J. Am. Coll. Cardiol. 77, 2693\u20132716 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1469_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ccep.2015.03.013","volume":"7","author":"MG Fradley","year":"2015","unstructured":"Fradley, M. G. & Moslehi, J. QT prolongation and oncology drug development. Card. Electrophysiol. Clin. 7, 341\u2013355 (2015).","journal-title":"Card. Electrophysiol. Clin."},{"key":"1469_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01102-1","volume":"23","author":"M Sestier","year":"2021","unstructured":"Sestier, M., Hillis, C., Fraser, G. & Leong, D. Bruton\u2019s tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation. Curr. Oncol. Rep. 23, 113 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"1469_CR58","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang, H. M., Okwuosa, T. M., Scarabelli, T., Moudgil, R. & Yeh, E. T. H. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J. Am. Coll. Cardiol. 70, 2552\u20132565 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1469_CR59","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1097\/HS9.0000000000000564","volume":"5","author":"TA Mulder","year":"2021","unstructured":"Mulder, T. A. et al. Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia. HemaSphere 5, e564 (2021).","journal-title":"HemaSphere"},{"key":"1469_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life10120344","volume":"10","author":"V Giudice","year":"2020","unstructured":"Giudice, V., Vecchione, C. & Selleri, C. Cardiotoxicity of novel targeted hematological therapies. Life 10, 1\u201322 (2020).","journal-title":"Life"},{"key":"1469_CR61","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","volume":"4","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos, M. et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: A substudy of the phase 3 ASPEN trial. Blood Adv. 4, 6009\u20136018 (2020).","journal-title":"Blood Adv."},{"key":"1469_CR62","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia, P. et al. Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 38, 2849\u20132861 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1469_CR63","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1200\/JCO.2020.38.15_suppl.8007","volume":"38","author":"CSL Tam","year":"2020","unstructured":"Tam, C. S. L. et al. ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstr\u00f6m macroglobulinemia (WM). J. Clin. Oncol. 38, 8007\u20138007 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1469_CR64","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","volume":"129","author":"BL Lampson","year":"2017","unstructured":"Lampson, B. L. et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood 129, 2581\u20132584 (2017).","journal-title":"Blood"},{"key":"1469_CR65","first-page":"13","volume":"45","author":"L Wang","year":"2020","unstructured":"Wang, L. & Wang, W. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non\u2011small cell lung cancer (Review). Oncol. Rep. 45, 13\u201328 (2020).","journal-title":"Oncol. Rep."},{"key":"1469_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9103346","volume":"9","author":"R Chung","year":"2020","unstructured":"Chung, R. et al. Hypertensive cardiotoxicity in cancer treatment\u2014systematic analysis of adjunct, conventional chemotherapy, and novel therapies\u2014epidemiology, incidence, and pathophysiology. J. Clin. Med. 9, 1\u201322 (2020).","journal-title":"J. Clin. Med."},{"key":"1469_CR67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir, H., Ethier, J. L., Lee, D. S., Thavendiranathan, P. & Amir, E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat. Rev. 53, 120\u2013127 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"1469_CR68","first-page":"1","volume":"1","author":"D Vaitiekus","year":"2017","unstructured":"Vaitiekus, D., Kastanjeda -Martines, E., Lingyt\u0117, E., Dambrauskas, L. & Juozaityt\u0117, E. Tyrosine kinase inhibitors induced cardiotoxicity. J. Med. Sci. Med. Sci. 1, 1\u201310 (2017).","journal-title":"J. Med. Sci. Med. Sci."},{"key":"1469_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0708-8","volume":"20","author":"M Agarwal","year":"2018","unstructured":"Agarwal, M., Thareja, N., Benjamin, M., Akhondi, A. & Mitchell, G. D. Tyrosine kinase inhibitor-induced hypertension. Curr. Oncol. Rep. 20, 65 (2018).","journal-title":"Curr. Oncol. Rep."},{"key":"1469_CR70","doi-asserted-by":"crossref","unstructured":"Turner, J. R., Karnad, D. R. & Kothari, S. Oncology Drug Therapy: Cardiotoxicity and the Discipline of Cardio-oncology. In: Cardiovascular Safety in Drug Development and Therapeutic Use. 201-221 (Adis, Cham. 2017).","DOI":"10.1007\/978-3-319-40347-2_10"},{"key":"1469_CR71","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","volume":"56","author":"MHW Kappers","year":"2010","unstructured":"Kappers, M. H. W. et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56, 675\u2013681 (2010).","journal-title":"Hypertension"},{"key":"1469_CR72","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/HJH.0000000000000550","volume":"33","author":"M Alivon","year":"2015","unstructured":"Alivon, M. et al. Large artery stiffness and hypertension after antiangiogenic drugs: Influence on cancer progression. J. Hypertens. 33, 1310\u20131317 (2015).","journal-title":"J. Hypertens."},{"key":"1469_CR73","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson, T. et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 134, 1919\u20131928 (2019).","journal-title":"Blood"},{"key":"1469_CR74","first-page":"1221","volume":"34","author":"T Satoh","year":"2013","unstructured":"Satoh, T. Tyrosine kinase inhibitor for pulmonary arterial hypertension. Ther. Res. 34, 1221\u20131223 (2013).","journal-title":"Ther. Res."},{"key":"1469_CR75","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani, D. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125, 2128\u20132137 (2012).","journal-title":"Circulation"},{"key":"1469_CR76","first-page":"142","volume":"91","author":"AK Mishra","year":"2020","unstructured":"Mishra, A. K., Sahu, K. K., Kaul, S. & Lal, A. Dasatinib induced pleuro-pericardial effusion. Acta Biomed. 91, 142\u2013143 (2020).","journal-title":"Acta Biomed."},{"key":"1469_CR77","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-021-00817-2","volume":"16","author":"A Goldman","year":"2021","unstructured":"Goldman, A. et al. Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: a retrospective, pharmacovigilance study. Target. Oncol. 16, 471\u2013483 (2021).","journal-title":"Target. Oncol."},{"key":"1469_CR78","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/ejh.13290","volume":"103","author":"P Bernardeschi","year":"2019","unstructured":"Bernardeschi, P., Pirrotta, M. T., Del Rosso, A., Fontanelli, G. & Milandri, C. Sudden ventricular fibrillation and death during ibrutinib therapy\u2014a case report. Eur. J. Haematol. 103, 442\u2013443 (2019).","journal-title":"Eur. J. Haematol."},{"key":"1469_CR79","doi-asserted-by":"publisher","first-page":"e101145","DOI":"10.1371\/journal.pone.0101145","volume":"9","author":"LI Faruque","year":"2014","unstructured":"Faruque, L. I. et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS ONE 9, e101145 (2014).","journal-title":"PLoS ONE"},{"key":"1469_CR80","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273\u20131283 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1469_CR81","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1469_CR82","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron, D. et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389, 1195\u20131205 (2017).","journal-title":"Lancet"},{"key":"1469_CR83","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","volume":"50","author":"MS Ewer","year":"2014","unstructured":"Ewer, M. S. et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur. J. Cancer 50, 2162\u20132170 (2014).","journal-title":"Eur. J. Cancer"},{"key":"1469_CR84","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMc1311795","volume":"369","author":"J Wittes","year":"2013","unstructured":"Wittes, J. Pazopanib versus sunitinib in renal cancer. N. Engl. J. Med. 369, 1968\u20131970 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1469_CR85","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","volume":"1","author":"PS Hall","year":"2013","unstructured":"Hall, P. S., Harshman, L. C., Srinivas, S. & Witteles, R. M. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Hear. Fail. 1, 72\u201378 (2013).","journal-title":"JACC Hear. Fail."},{"key":"1469_CR86","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","volume":"165","author":"T Dahl\u00e9n","year":"2016","unstructured":"Dahl\u00e9n, T. et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia. Ann. Intern. Med. 165, 161\u2013166 (2016).","journal-title":"Ann. Intern. Med."},{"key":"1469_CR87","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus, A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30, 1044\u20131054 (2016).","journal-title":"Leukemia"},{"key":"1469_CR88","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi, J. J. & Deininger, M. Tyrosine kinase inhibitor\u2013associated cardiovascular toxicity in chronic myeloid leukemia. J. Clin. Oncol. 33, 4210 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1469_CR89","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/ajh.24174","volume":"90","author":"NP Shah","year":"2015","unstructured":"Shah, N. P. et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am. J. Hematol. 90, 1060\u20131064 (2015).","journal-title":"Am. J. Hematol."},{"key":"1469_CR90","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2016003889","volume":"1","author":"LC Fox","year":"2017","unstructured":"Fox, L. C. et al. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv. 1, 802\u2013811 (2017).","journal-title":"Blood Adv."},{"key":"1469_CR91","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijcard.2019.04.051","volume":"288","author":"G Caocci","year":"2019","unstructured":"Caocci, G. et al. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int. J. Cardiol. 288, 124\u2013127 (2019).","journal-title":"Int. J. Cardiol."},{"key":"1469_CR92","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles, F. J. et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27, 1310\u20131315 (2013).","journal-title":"Leukemia"},{"key":"1469_CR93","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes, J. E. et al. Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132, 393\u2013404 (2018).","journal-title":"Blood"},{"key":"1469_CR94","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrc3366","volume":"12","author":"B Sennino","year":"2012","unstructured":"Sennino, B. & McDonald, D. M. Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 12, 699 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1469_CR95","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1634\/theoncologist.2012-0388","volume":"18","author":"KR Sampat","year":"2013","unstructured":"Sampat, K. R. & O\u2019Neil, B. Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist 18, 430 (2013).","journal-title":"Oncologist"},{"key":"1469_CR96","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.18632\/oncotarget.23429","volume":"9","author":"D Liu","year":"2018","unstructured":"Liu, D., Ma, X., Xiao, D., Jia, Y. & Wang, Y. Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and metaanalysis. Oncotarget 9, 8120\u20138132 (2018).","journal-title":"Oncotarget"},{"key":"1469_CR97","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3389\/fphys.2017.00651","volume":"8","author":"JV Shim","year":"2017","unstructured":"Shim, J. V. et al. Mechanistic systems modeling to improve understanding and prediction of cardiotoxicity caused by targeted cancer therapeutics. Front. Physiol. 8, 651 (2017).","journal-title":"Front. Physiol."},{"key":"1469_CR98","doi-asserted-by":"crossref","unstructured":"Stuhlmiller, T. J. et al. Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor recepto. J. Am. Heart Assoc. 6, e006635 (2017).","DOI":"10.1161\/JAHA.117.006635"},{"key":"1469_CR99","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3892\/ol.2020.12355","volume":"21","author":"Y Li","year":"2021","unstructured":"Li, Y., Wang, W., Gao, R., Xu, X. & Zhang, Y. Genome-wide prioritization reveals novel gene signatures associated with cardiotoxic effects of tyrosine kinase inhibitors. Oncol. Lett. 21, 94 (2021).","journal-title":"Oncol. Lett."},{"key":"1469_CR100","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/med.21463","volume":"38","author":"PP Zheng","year":"2018","unstructured":"Zheng, P. P., Li, J. & Kros, J. M. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med. Res. Rev. 38, 325\u2013376 (2018).","journal-title":"Med. Res. Rev."},{"key":"1469_CR101","doi-asserted-by":"publisher","first-page":"630480","DOI":"10.3389\/fcvm.2020.630480","volume":"7","author":"CJ McMullen","year":"2021","unstructured":"McMullen, C. J., Chalmers, S., Wood, R., Cunningham, M. R. & Currie, S. Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium\/Calmodulin Dependent Protein Kinase II. Front. Cardiovasc. Med. 7, 630480 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"1469_CR102","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-022-01018-7","volume":"7","author":"L Li","year":"2022","unstructured":"Li, L. et al. CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity. Signal Transduct. Target. Ther. 7, 190 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1469_CR103","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","volume":"115","author":"AP Singh","year":"2019","unstructured":"Singh, A. P. et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc. Res. 115, 966\u2013977 (2019).","journal-title":"Cardiovasc. Res."},{"key":"1469_CR104","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","volume":"11","author":"JM Gozgit","year":"2012","unstructured":"Gozgit, J. M. et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 11, 690\u2013699 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"1469_CR105","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3389\/fcell.2020.00434","volume":"8","author":"W Ma","year":"2020","unstructured":"Ma, W., Wei, S., Zhang, B. & Li, W. Molecular mechanisms of cardiomyocyte death in drug-induced cardiotoxicity. Front. Cell Dev. Biol. 8, 434 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1469_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1749-8090-6-54","volume":"6","author":"XH Xu","year":"2011","unstructured":"Xu, X. H. et al. VEGF attenuates development from cardiac hypertrophy to heart failure after aortic stenosis through mitochondrial mediated apoptosis and cardiomyocyte proliferation. J. Cardiothorac. Surg. 6, 1\u20139 (2011).","journal-title":"J. Cardiothorac. Surg."},{"key":"1469_CR107","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1096\/fj.09-143180","volume":"24","author":"L Zentilin","year":"2010","unstructured":"Zentilin, L. et al. Cardiomyocyte VEGFR\u20101 activation by VEGF\u2010B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J. 24, 1467\u20131478 (2010).","journal-title":"FASEB J."},{"key":"1469_CR108","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu, T. F. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011\u20132019 (2007).","journal-title":"Lancet"},{"key":"1469_CR109","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force, T., Krause, D. S. & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332\u2013344 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"1469_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.01106","volume":"11","author":"J Bouitbir","year":"2020","unstructured":"Bouitbir, J., Panajatovic, M. V., Frechard, T., Roos, N. J. & Kr\u00e4henb\u00fchl, S. Imatinib and dasatinib provoke mitochondrial dysfunction leading to oxidative stress in C2C12 myotubes and human RD cells. Front. Pharmacol. 11, 1 (2020).","journal-title":"Front. Pharmacol."},{"key":"1469_CR111","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacbts.2017.12.007","volume":"3","author":"R Truitt","year":"2018","unstructured":"Truitt, R. et al. Increased afterload augments sunitinib-induced cardiotoxicity in an engineered cardiac microtissue model. JACC Basic Transl. Sci. 3, 265\u2013276 (2018).","journal-title":"JACC Basic Transl. Sci."},{"key":"1469_CR112","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","volume":"2","author":"R Kerkela","year":"2009","unstructured":"Kerkela, R. et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2, 15\u201325 (2009).","journal-title":"Clin. Transl. Sci."},{"key":"1469_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23630-w","volume":"8","author":"C Schneider","year":"2018","unstructured":"Schneider, C. et al. The anti-cancer multikinase inhibitor sorafenib impairs cardiac contractility by reducing phospholamban phosphorylation and sarcoplasmic calcium transients. Sci. Rep. 8, 5295 (2018).","journal-title":"Sci. Rep."},{"key":"1469_CR114","first-page":"307","volume":"18","author":"J Zhu","year":"2021","unstructured":"Zhu, J. & Bian, S. Y. Late-chronic cardiotoxicity and heart failure caused by ibrutinib: a case report and literature review. J. Geriatr. Cardiol. 18, 307\u2013311 (2021).","journal-title":"J. Geriatr. Cardiol."},{"key":"1469_CR115","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/VHRM.S108874","volume":"13","author":"N Aghel","year":"2017","unstructured":"Aghel, N., Delgado, D. H. & Lipton, J. H. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc. Health Risk Manag 13, 293 (2017).","journal-title":"Vasc. Health Risk Manag"},{"key":"1469_CR116","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCRESAHA.118.312706","volume":"123","author":"NE Ibrahim","year":"2018","unstructured":"Ibrahim, N. E. & Januzzi, J. L. Established and emerging roles of biomarkers in heart failure. Circ. Res. 123, 614\u2013629 (2018).","journal-title":"Circ. Res."},{"key":"1469_CR117","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","volume":"101","author":"N Pavo","year":"2015","unstructured":"Pavo, N. et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 101, 1874\u20131880 (2015).","journal-title":"Heart"},{"key":"1469_CR118","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pcad.2010.05.006","volume":"53","author":"G Curigliano","year":"2010","unstructured":"Curigliano, G., Mayer, E. L., Burstein, H. J., Winer, E. P. & Goldhirsch, A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog. Cardiovasc. Dis. 53, 94\u2013104 (2010).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"1469_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6616265","volume":"2021","author":"A Bojan","year":"2021","unstructured":"Bojan, A., Torok-Vistai, T. & Parvu, A. Assessment and management of cardiotoxicity in hematologic malignancies. Dis. Markers 2021, 1\u201310 (2021).","journal-title":"Dis. Markers"},{"key":"1469_CR120","doi-asserted-by":"publisher","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","volume":"9","author":"J Alexandre","year":"2020","unstructured":"Alexandre, J. et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the american and european cardio-oncology guidelines. J. Am. Heart Assoc. 9, e018403 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"1469_CR121","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano, J. L. et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. 37, 2768\u20132801 (2016).","journal-title":"Eur. Heart J."},{"key":"1469_CR122","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ejhf.1165","volume":"20","author":"P Ameri","year":"2018","unstructured":"Ameri, P. et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur. J. Heart Fail. 20, 879\u2013887 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"1469_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox9070641","volume":"9","author":"V Mercurio","year":"2020","unstructured":"Mercurio, V. et al. Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC). Antioxidants 9, 1\u201320 (2020).","journal-title":"Antioxidants"},{"key":"1469_CR124","doi-asserted-by":"crossref","first-page":"21165","DOI":"10.1161\/JAHA.121.021165","volume":"10","author":"AA van de Bovenkamp","year":"2021","unstructured":"van de Bovenkamp, A. A. et al. Validation of the 2016 ase\/eacvi guideline for diastolic dysfunction in patients with unexplained dyspnea and a preserved left ventricular ejection fraction. J. Am. Heart Assoc. 10, 21165 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"1469_CR125","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou, E. K. et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol. 4, 1007 (2019).","journal-title":"JAMA Cardiol."},{"key":"1469_CR126","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3892\/ol.2020.12361","volume":"21","author":"J Guan","year":"2021","unstructured":"Guan, J. & Zhang, M. Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer (Review). Oncol. Lett. 21, 100 (2021).","journal-title":"Oncol. Lett."},{"key":"1469_CR127","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.mric.2019.04.001","volume":"27","author":"T Ferreira de Souza","year":"2019","unstructured":"Ferreira de Souza, T., Quinaglia, T., Neilan, T. G. & Coelho-Filho, O. R. Assessment of cardiotoxicity of cancer chemotherapy: the value of cardiac MRI. Magn. Reson. Imaging Clin. N. Am. 27, 533 (2019).","journal-title":"Magn. Reson. Imaging Clin. N. Am."},{"key":"1469_CR128","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","volume":"137","author":"LS Mehta","year":"2018","unstructured":"Mehta, L. S. et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 137, e30\u2013e66 (2018).","journal-title":"Circulation"},{"key":"1469_CR129","doi-asserted-by":"publisher","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","volume":"10","author":"L Michel","year":"2018","unstructured":"Michel, L., Rassaf, T. & Totzeck, M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J. Thorac. Dis. 10, S4282\u2013S4295 (2018).","journal-title":"J. Thorac. Dis."},{"key":"1469_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom11020166","volume":"11","author":"J Bi","year":"2021","unstructured":"Bi, J., Garg, V. & Yates, A. R. Galectin-3 and sST2 as prognosticators for heart failure requiring extracorporeal life support: Jack n\u2019 Jill. Biomolecules 11, 1\u201310 (2021).","journal-title":"Biomolecules"},{"key":"1469_CR131","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/BIC.S31798","volume":"8s2","author":"C Henri","year":"2016","unstructured":"Henri, C., Heinonen, T. & Tardif, J.-C. The role of biomarkers in decreasing risk of cardiac toxicity after cancer therapy. Biomark. Cancer 8s2, 39\u201345 (2016).","journal-title":"Biomark. Cancer"},{"key":"1469_CR132","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/medicina57070701","volume":"57","author":"W Bargie\u0142","year":"2021","unstructured":"Bargie\u0142, W. et al. Recognized and potentially new biomarkers\u2014their role in diagnosis and prognosis of cardiovascular disease. Medicina 57, 701 (2021).","journal-title":"Medicina"},{"key":"1469_CR133","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ijms18030625","volume":"18","author":"OV Ancker","year":"2017","unstructured":"Ancker, O. V., Wehland, M., Bauer, J., Infanger, M. & Grimm, D. The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors. Int. J. Mol. Sci. 18, 625 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"1469_CR134","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","volume":"22","author":"PA Pophali","year":"2016","unstructured":"Pophali, P. A. & Patnaik, M. M. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 22, 40 (2016).","journal-title":"Cancer J."},{"key":"1469_CR135","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","volume":"11","author":"H Haguet","year":"2020","unstructured":"Haguet, H. et al. The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study. Front. Pharmacol. 11, 1007 (2020).","journal-title":"Front. Pharmacol."},{"key":"1469_CR136","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/157340308784245810","volume":"4","author":"TH Khan","year":"2008","unstructured":"Khan, T. H., Farooqui, F. A. & Niazi, K. Critical review of the ankle brachial index. Curr. Cardiol. Rev. 4, 101 (2008).","journal-title":"Curr. Cardiol. Rev."},{"key":"1469_CR137","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann, J. L. et al. European LeukemiaNet recommendations for the management and avoidance of adverseevents of treatment in chronic myeloid leukaemia. Leukemia 30, 1648 (2016).","journal-title":"Leukemia"},{"key":"1469_CR138","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"M Galderisi","year":"2017","unstructured":"Galderisi, M. et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur. Hear. J. Cardiovasc. Imaging 18, 1301\u20131310 (2017).","journal-title":"Eur. Hear. J. Cardiovasc. Imaging"},{"key":"1469_CR139","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/ehjci\/jev309","volume":"17","author":"D Muraru","year":"2016","unstructured":"Muraru, D. et al. New speckle-tracking algorithm for right ventricular volume analysis from three-dimensional echocardiographic data sets: validation with cardiac magnetic resonance and comparison with the previous analysis tool. Eur. Hear. J. Cardiovasc. Imaging 17, 1279\u20131289 (2016).","journal-title":"Eur. Hear. J. Cardiovasc. Imaging"},{"key":"1469_CR140","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with ibrutinib. J. Am. Coll. Cardiol. 74, 1667\u20131678 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1469_CR141","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/ckj\/sfaa188","volume":"14","author":"CL Ramspek","year":"2021","unstructured":"Ramspek, C. L., Jager, K. J., Dekker, F. W., Zoccali, C. & Van DIepen, M. External validation of prognostic models: what, why, how, when and where? Clin. Kidney J. 14, 49 (2021).","journal-title":"Clin. Kidney J."},{"key":"1469_CR142","first-page":"263","volume":"38","author":"E Mouhayar","year":"2011","unstructured":"Mouhayar, E. & Salahudeen, A. Hypertension in cancer patients. Tex. Hear. Inst. J. 38, 263 (2011).","journal-title":"Tex. Hear. Inst. J."},{"key":"1469_CR143","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12688\/f1000research.12598.1","volume":"7","author":"TM Markman","year":"2019","unstructured":"Markman, T. M. & Markman, M. Cardio-oncology: management of cardiovascular toxicity. F1000Research. 7, 113 (2019).","journal-title":"F1000Research."},{"key":"1469_CR144","doi-asserted-by":"publisher","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","volume":"6","author":"A Porta-S\u00e1nchez","year":"2017","unstructured":"Porta-S\u00e1nchez, A. et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J. Am. Heart Assoc. 6, e007724 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"1469_CR145","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1080\/10428194.2017.1315115","volume":"58","author":"KL Chai","year":"2017","unstructured":"Chai, K. L. et al. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk. Lymphoma 58, 2811\u20132814 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"1469_CR146","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","volume":"113","author":"H Lee","year":"2021","unstructured":"Lee, H., Basso, I. N. & Kim, D. D. H. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int. J. Hemat. 113, 632\u2013641 (2021).","journal-title":"Int. J. Hemat."},{"key":"1469_CR147","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon, C. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149, 315\u2013352 (2016).","journal-title":"Chest"},{"key":"1469_CR148","doi-asserted-by":"publisher","first-page":"E000102","DOI":"10.1161\/HCQ.0000000000000102","volume":"14","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt, B. et al. 2021 ACC\/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure). Circ. Cardiovasc. Qual. Outcomes 14, E000102 (2021).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"1469_CR149","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/ehf2.13365","volume":"8","author":"A Bikiewicz","year":"2021","unstructured":"Bikiewicz, A., Banach, M., von Haehling, S., Maciejewski, M. & Bielecka-Dabrowa, A. Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications. Esc. Heart Fail. 8, 2397\u20132418 (2021).","journal-title":"Esc. Heart Fail."},{"key":"1469_CR150","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","volume":"89","author":"J Herrmann","year":"2014","unstructured":"Herrmann, J. et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin. Proc. 89, 1287\u20131306 (2014).","journal-title":"Mayo Clin. Proc."},{"key":"1469_CR151","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11936-015-0421-y","volume":"17","author":"Y Xie","year":"2015","unstructured":"Xie, Y. et al. Breast cancer survivorship and cardiovascular disease: emerging approaches in cardio-oncology. Curr. Treat. Options Cardiovasc. Med. 17, 60 (2015).","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"1469_CR152","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana, J. C. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 27, 911\u2013939 (2014).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"1469_CR153","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.3390\/cancers13235961","volume":"13","author":"A De Leo","year":"2021","unstructured":"De Leo, A., Di Simone, E., Spano, A., Puliani, G. & Petrone, F. Nursing management and adverse events in thyroid cancer treatments with tyrosine kinase inhibitors. A narrative review. Cancers 13, 5961 (2021).","journal-title":"Cancers"},{"key":"1469_CR154","doi-asserted-by":"publisher","first-page":"985780","DOI":"10.4061\/2011\/985780","volume":"2011","author":"ME Cabanillas","year":"2011","unstructured":"Cabanillas, M. E., Hu, M. I., Durand, J. B. & Busaidy, N. L. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J. Thyroid. Res. 2011, 985780 (2011).","journal-title":"J. Thyroid. Res."},{"key":"1469_CR155","unstructured":"Liu, C. et al. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J. Cancer Res. Clin. Oncol. 1\u201312 (2022)."},{"key":"1469_CR156","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba, T. & McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96, 1788\u20131795 (2007).","journal-title":"Br. J. Cancer"},{"key":"1469_CR157","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3747\/co.v18i3.877","volume":"18","author":"V Hirsh","year":"2011","unstructured":"Hirsh, V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr. Oncol. 18, 126\u2013138 (2011).","journal-title":"Curr. Oncol."},{"key":"1469_CR158","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3747\/co.2007.96","volume":"14","author":"JA Maroun","year":"2007","unstructured":"Maroun, J. A. et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr. Oncol. 14, 13\u201320 (2007).","journal-title":"Curr. Oncol."},{"key":"1469_CR159","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"J Hartmann","year":"2009","unstructured":"Hartmann, J., Haap, M., Kopp, H.-G. & Lipp, H.-P. Tyrosine Kinase Inhibitors\u2014a review on pharmacology, metabolism and side effects. Curr. Drug Metab. 10, 470\u2013481 (2009).","journal-title":"Curr. Drug Metab."},{"key":"1469_CR160","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10637-008-9146-z","volume":"27","author":"TW Flaig","year":"2009","unstructured":"Flaig, T. W. et al. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest. N. Drugs 27, 83\u201387 (2009).","journal-title":"Invest. N. Drugs"},{"key":"1469_CR161","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.3748\/wjg.14.6096","volume":"14","author":"H Hur","year":"2008","unstructured":"Hur, H. et al. Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. World J. Gastroenterol. 14, 6096\u20136099 (2008).","journal-title":"World J. Gastroenterol."},{"key":"1469_CR162","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10456-010-9197-6","volume":"14","author":"M Walraven","year":"2011","unstructured":"Walraven, M. et al. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 14, 135\u2013141 (2011).","journal-title":"Angiogenesis"},{"key":"1469_CR163","doi-asserted-by":"publisher","first-page":"153473542092849","DOI":"10.1177\/1534735420928493","volume":"19","author":"KR Secombe","year":"2020","unstructured":"Secombe, K. R. et al. Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome. Integr. Cancer Ther. 19, 1534735420928493 (2020).","journal-title":"Integr. Cancer Ther."},{"key":"1469_CR164","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.clpt.2006.04.007","volume":"80","author":"JF Lu","year":"2006","unstructured":"Lu, J. F. et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin. Pharmacol. Ther. 80, 136\u2013145 (2006).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1469_CR165","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.ejca.2006.03.029","volume":"42","author":"MVan Glabbeke","year":"2006","unstructured":"Glabbeke, M. Van et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr. Eur. J. Cancer 42, 2277\u20132285 (2006).","journal-title":"Eur. J. Cancer"},{"key":"1469_CR166","unstructured":"P\u0142u\u017ca\u0144ski, A. & Pi\u00f3rek, A. Side effects of tyrosine kinase inhibitors-management guidelines. Oncol. Clin. Pr. 12, 113\u2013118 (2016)."},{"key":"1469_CR167","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","volume":"11","author":"L Caldemeyer","year":"2016","unstructured":"Caldemeyer, L., Dugan, M., Edwards, J. & Akard, L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr. Hematol. Malig. Rep. 11, 71\u201379 (2016).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"1469_CR168","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"20","author":"A Lipsky","year":"2020","unstructured":"Lipsky, A. & Lamanna, N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol. Am. Soc. Hematol. Educ. Program 20, 336\u2013345 (2020).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"1469_CR169","doi-asserted-by":"publisher","first-page":"16052","DOI":"10.18632\/oncotarget.14109","volume":"8","author":"YK Chae","year":"2017","unstructured":"Chae, Y. K. et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget 8, 16052\u201316074 (2017).","journal-title":"Oncotarget"},{"key":"1469_CR170","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1002\/onco.13552","volume":"26","author":"ME Lacouture","year":"2021","unstructured":"Lacouture, M. E. et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist 26, e316\u2013e326 (2021).","journal-title":"Oncologist"},{"key":"1469_CR171","first-page":"115","volume":"7","author":"G Keller-von Amsberg","year":"2013","unstructured":"Keller-von Amsberg, G. & Schafhausen, P. Bosutinib in the management of chronic myelogenous leukemia. Biologics 7, 115\u2013122 (2013).","journal-title":"Biologics"},{"key":"1469_CR172","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clml.2015.12.003","volume":"16","author":"K Sasaki","year":"2016","unstructured":"Sasaki, K. et al. Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and\/or renal dysfunction. Clin. Lymphoma Myeloma Leuk. 16, 152\u2013162 (2016).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1469_CR173","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00277-015-2318-y","volume":"94","author":"D Rea","year":"2015","unstructured":"Rea, D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann. Hematol. 94, 149\u2013158 (2015).","journal-title":"Ann. Hematol."},{"key":"1469_CR174","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/toxres\/tfab026","volume":"10","author":"G Tao","year":"2021","unstructured":"Tao, G. & Chityala, P. K. Epidermal growth factor receptor inhibitor-induced diarrhea: Clinical incidence, toxicological mechanism, and management. Toxicol. Res. 10, 476\u2013486 (2021).","journal-title":"Toxicol. Res."},{"key":"1469_CR175","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","volume":"77","author":"L Rimassa","year":"2019","unstructured":"Rimassa, L., Danesi, R., Pressiani, T. & Merle, P. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat. Rev. 77, 20\u201328 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"1469_CR176","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.2147\/OTT.S147438","volume":"10","author":"P Chen","year":"2017","unstructured":"Chen, P., Chen, F. & Zhou, B. Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis. Onco. Targets Ther. 10, 5391\u20135403 (2017).","journal-title":"Onco. Targets Ther."},{"key":"1469_CR177","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/era.13.31","volume":"13","author":"JCH Yang","year":"2013","unstructured":"Yang, J. C. H. et al. Diarrhea associated with afatinib: An oral ErbB family blocker. Expert Rev. Anticancer Ther. 13, 729\u2013736 (2013).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1469_CR178","doi-asserted-by":"publisher","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","volume":"7","author":"A Som","year":"2019","unstructured":"Som, A. et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J. Clin. Cases. 7, 405\u2013418 (2019).","journal-title":"World J. Clin. Cases."},{"key":"1469_CR179","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling, L. et al. Tolerability of BRAF\/MEK inhibitor combinations: Adverse event evaluation and management. ESMO Open 4, 491 (2019).","journal-title":"ESMO Open"},{"key":"1469_CR180","doi-asserted-by":"publisher","first-page":"2120165","DOI":"10.1001\/jamanetworkopen.2021.20165","volume":"4","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis. JAMA Netw. Open. 4, 2120165 (2021).","journal-title":"JAMA Netw. Open."},{"key":"1469_CR181","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio, G. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362, 2251\u20132259 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1469_CR182","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah, R. R., Morganroth, J. & Shah, D. R. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 36, 491\u2013503 (2013).","journal-title":"Drug Saf."},{"key":"1469_CR183","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","volume":"6","author":"NE Omar","year":"2021","unstructured":"Omar, N. E. et al. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS). ESMO Open 6, 100315 (2021).","journal-title":"ESMO Open"},{"key":"1469_CR184","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","volume":"14","author":"CS Tam","year":"2021","unstructured":"Tam, C. S., Ou, Y. C., Trotman, J. & Opat, S. Clinical pharmacology and PK\/PD translation of the second-generation Bruton\u2019s tyrosine kinase inhibitor, zanubrutinib. Expert Rev. Clin. Pharmacol. 14, 1329\u20131344 (2021).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"1469_CR185","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","volume":"102","author":"CF Xu","year":"2010","unstructured":"Xu, C. F. et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert\u2019s syndrome UGT1A1 polymorphism. Br. J. Cancer 102, 1371\u20131377 (2010).","journal-title":"Br. J. Cancer"},{"key":"1469_CR186","first-page":"443","volume":"71","author":"SV Keisner","year":"2011","unstructured":"Keisner, S. V. & Shah, S. R. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71, 443\u2013454 (2011).","journal-title":"Drugs"},{"key":"1469_CR187","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.2147\/CMAR.S237968","volume":"12","author":"J Qian","year":"2020","unstructured":"Qian, J. et al. Tyrosine kinase inhibitor-related hepatotoxicity in patients with advanced lung adenocarcinoma: a real-world retrospective study. Cancer Manag. Res. 12, 3293\u20133299 (2020).","journal-title":"Cancer Manag. Res."},{"key":"1469_CR188","first-page":"291","volume":"11","author":"R Pezzilli","year":"2010","unstructured":"Pezzilli, R., Corinaldesi, R. & Morselli-Labate, A. M. Tyrosine kinase inhibitors and acute pancreatitis. J. Pancreas 11, 291\u2013293 (2010).","journal-title":"J. Pancreas"},{"key":"1469_CR189","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1083\/jcb.109.1.429","volume":"109","author":"GF Pierce","year":"1989","unstructured":"Pierce, G. F. et al. Platelet-derived growth factor and transforming growth factor-\u03b2 enhance tissue repair activities by unique mechanisms. J. Cell Biol. 109, 429\u2013440 (1989).","journal-title":"J. Cell Biol."},{"key":"1469_CR190","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jss.2005.12.032","volume":"134","author":"T Ueda","year":"2006","unstructured":"Ueda, T. et al. Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis. J. Surg. Res. 134, 223\u2013230 (2006).","journal-title":"J. Surg. Res."},{"key":"1469_CR191","doi-asserted-by":"publisher","first-page":"1012268","DOI":"10.3389\/fonc.2022.1012268","volume":"12","author":"R Pasquale","year":"2022","unstructured":"Pasquale, R. et al. Case report: pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event. Front. Oncol. 12, 1012268 (2022).","journal-title":"Front. Oncol."},{"key":"1469_CR192","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","volume":"58","author":"N Heidary","year":"2008","unstructured":"Heidary, N., Naik, H. & Burgin, S. Chemotherapeutic agents and the skin: an update. J. Am. Acad. Dermatol. 58, 545\u2013570 (2008).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1469_CR193","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/er.2009-0031","volume":"31","author":"L Ye","year":"2010","unstructured":"Ye, L., Santarpia, L. & Gagel, R. F. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr. Rev. 31, 578\u2013599 (2010).","journal-title":"Endocr. Rev."},{"key":"1469_CR194","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","volume":"151","author":"RC Zuo","year":"2015","unstructured":"Zuo, R. C. et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 151, 170\u2013177 (2015).","journal-title":"JAMA Dermatol."},{"key":"1469_CR195","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","volume":"152","author":"T Terada","year":"2015","unstructured":"Terada, T., Noda, S. & Inui, K. I. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol. Ther. 152, 125\u2013134 (2015).","journal-title":"Pharmacol. Ther."},{"key":"1469_CR196","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1124\/mol.110.070862","volume":"80","author":"N Yamamoto","year":"2011","unstructured":"Yamamoto, N., Honma, M. & Suzuki, H. Off-target serine\/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders. Mol. Pharmacol. 80, 466\u2013475 (2011).","journal-title":"Mol. Pharmacol."},{"key":"1469_CR197","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ad.2013.01.009","volume":"105","author":"M Pretel-Irazabal","year":"2014","unstructured":"Pretel-Irazabal, M., Tuneu-Valls, A. & Ormaechea-P\u00e9rez, N. Adverse skin effects of imatinib, a tyrosine kinase inhibitor. Actas Dermosifiliogr. 105, 655\u2013662 (2014).","journal-title":"Actas Dermosifiliogr."},{"key":"1469_CR198","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.leukres.2004.05.015","volume":"29","author":"EG Dib","year":"2005","unstructured":"Dib, E. G., Ifthikharuddin, J. J., Scott, G. A. & Partilo, S. R. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. Leuk. Res. 29, 233\u2013234 (2005).","journal-title":"Leuk. Res."},{"key":"1469_CR199","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/archderm.141.3.368","volume":"141","author":"SJ Ayirookuzhi","year":"2005","unstructured":"Ayirookuzhi, S. J., Ma, L., Ramshesh, P. & Mills, G. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch. Dermatol. 141, 368\u2013370 (2005).","journal-title":"Arch. Dermatol."},{"key":"1469_CR200","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bjh.14302","volume":"180","author":"DJ Iberri","year":"2018","unstructured":"Iberri, D. J. et al. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br. J. Haematol. 180, 164\u2013166 (2018).","journal-title":"Br. J. Haematol."},{"key":"1469_CR201","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","volume":"21","author":"V Sibaud","year":"2020","unstructured":"Sibaud, V. et al. Dermatological toxicities of Bruton\u2019s tyrosine kinase inhibitors. Am. J. Clin. Dermatol. 21, 799\u2013812 (2020).","journal-title":"Am. J. Clin. Dermatol."},{"key":"1469_CR202","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1046\/j.1365-2141.2002.03499.x","volume":"117","author":"LT Hsiao","year":"2002","unstructured":"Hsiao, L. T. et al. Stevens-Johnson syndrome after treatment with STI571: A case report. Br. J. Haematol. 117, 620\u2013622 (2002).","journal-title":"Br. J. Haematol."},{"key":"1469_CR203","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1081-1206(10)60016-6","volume":"97","author":"RP Nelson","year":"2006","unstructured":"Nelson, R. P. et al. Desensitization to imatinib in patients with leukemia. Ann. Allergy, Asthma Immunol. 97, 216\u2013222 (2006).","journal-title":"Ann. Allergy, Asthma Immunol."},{"key":"1469_CR204","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1200\/JCO.2006.06.5318","volume":"24","author":"P Hamberg","year":"2006","unstructured":"Hamberg, P. et al. Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J. Clin. Oncol. 24, e30\u2013e31 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1469_CR205","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1096\/fj.06-6910com","volume":"21","author":"R H\u00e4gerkvist","year":"2007","unstructured":"H\u00e4gerkvist, R., Sandler, S., Mokhtari, D. & Welsh, N. Amelioration of diabetes by imatinib mesylate (Gleevec\u00ae): role of \u2010cell NF\u2010KB activation and anti\u2010apoptotic preconditioning. FASEB J. 21, 618\u2013628 (2007).","journal-title":"FASEB J."},{"key":"1469_CR206","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/sj.bjc.6604709","volume":"99","author":"B Billemont","year":"2008","unstructured":"Billemont, B. et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 99, 1380\u20131382 (2008).","journal-title":"Br. J. Cancer"},{"key":"1469_CR207","doi-asserted-by":"publisher","first-page":"R233","DOI":"10.1677\/ERC-10-0082","volume":"17","author":"MB Lodish","year":"2010","unstructured":"Lodish, M. B. & Stratakis, C. A. Endocrine side effects of broad-acting kinase inhibitors. Endocr. Relat. Cancer 17, R233 (2010).","journal-title":"Endocr. Relat. Cancer"},{"key":"1469_CR208","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MWN Deininger","year":"2003","unstructured":"Deininger, M. W. N., O\u2019Brien, S. G., Ford, J. M. & Druker, B. J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21, 1637\u20131647 (2003).","journal-title":"J. Clin. Oncol."},{"key":"1469_CR209","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa051140","volume":"354","author":"E Berman","year":"2006","unstructured":"Berman, E. et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N. Engl. J. Med. 354, 2006\u20132013 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1469_CR210","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1210\/jc.2008-2324","volume":"94","author":"S O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan, S. et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J. Clin. Endocrinol. Metab. 94, 1131\u20131136 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1469_CR211","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/jbmr.85","volume":"25","author":"K Vandyke","year":"2010","unstructured":"Vandyke, K. et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J. Bone Miner. Res. 25, 1759\u20131770 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"1469_CR212","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","volume":"6","author":"F Torino","year":"2009","unstructured":"Torino, F., Corsello, S. M., Longo, R., Barnabei, A. & Gasparini, G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat. Rev. Clin. Oncol. 6, 219\u2013228 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1469_CR213","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","volume":"78","author":"JWB De Groot","year":"2005","unstructured":"De Groot, J. W. B., Zonnenberg, B. A., Plukker, J. T. M., Van Der Graaf, W. T. A. & Links, T. P. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin. Pharmacol. Ther. 78, 433\u2013438 (2005).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1469_CR214","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin. Cancer Res. 9, 327\u2013337 (2003).","journal-title":"Clin. Cancer Res."},{"key":"1469_CR215","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","volume":"12","author":"EP Rock","year":"2007","unstructured":"Rock, E. P. et al. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12, 107\u2013113 (2007).","journal-title":"Oncologist"},{"key":"1469_CR216","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2165\/00044011-200929070-00007","volume":"29","author":"P Ballardini","year":"2009","unstructured":"Ballardini, P., Margutti, G., Aliberti, C. & Manfredini, R. Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma. Clin. Drug Investig. 29, 487\u2013490 (2009).","journal-title":"Clin. Drug Investig."},{"key":"1469_CR217","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes, J. E. et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial. J. Clin. Oncol. 34, 2333\u20132340 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1469_CR218","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf, T. H. et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: Results from the 24-month follow-up of the BELA trial. Br. J. Haematol. 168, 69\u201381 (2015).","journal-title":"Br. J. Haematol."},{"key":"1469_CR219","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","volume":"176","author":"A Bergeron","year":"2007","unstructured":"Bergeron, A. et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: A case series. Am. J. Respir. Crit. Care Med. 176, 814\u2013818 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1469_CR220","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/MAJ.0b013e3181ae9227","volume":"338","author":"M Goldblatt","year":"2009","unstructured":"Goldblatt, M., Huggins, J. T., Doelken, P., Gurung, P. & Sahn, S. A. Dasatinib-induced pleural effusions: A lymphatic network disorder? Am. J. Med. Sci. 338, 414\u2013417 (2009).","journal-title":"Am. J. Med. Sci."},{"key":"1469_CR221","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.17654","volume":"194","author":"P Rousselot","year":"2021","unstructured":"Rousselot, P. et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br. J. Haematol. 194, 393\u2013402 (2021).","journal-title":"Br. J. Haematol."},{"key":"1469_CR222","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","volume":"123","author":"CH Suh","year":"2018","unstructured":"Suh, C. H. et al. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer 123, 60\u201369 (2018).","journal-title":"Lung Cancer"},{"key":"1469_CR223","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/1759-7714.13790","volume":"12","author":"H Kanemura","year":"2021","unstructured":"Kanemura, H., Takeda, M., Shimizu, S. & Nakagawa, K. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14. Thorac. Cancer 12, 549\u2013552 (2021).","journal-title":"Thorac. Cancer"},{"key":"1469_CR224","doi-asserted-by":"crossref","unstructured":"Hashiguchi, M. H. et al. Successful tepotinib challenge after capmatinib-induced interstitial lung disease in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation: case report. JTO Clin. Res. Rep. 3, (2022).","DOI":"10.1016\/j.jtocrr.2021.100271"},{"key":"1469_CR225","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","volume":"28","author":"X Le","year":"2022","unstructured":"Le, X. et al. Tepotinib efficacy and safety in patients with met exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice. Clin. Cancer Res. 28, 1117\u20131126 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1469_CR226","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22020792","volume":"22","author":"T Ohmori","year":"2021","unstructured":"Ohmori, T. et al. Molecular and clinical features of egfr-tki-associated lung injury. Int. J. Mol. Sci. 22, 1\u201318 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1469_CR227","doi-asserted-by":"publisher","first-page":"11809","DOI":"10.3390\/ijms231911809","volume":"23","author":"LW Tseng","year":"2022","unstructured":"Tseng, L. W., Chang, J. W. C. & Wu, C. E. Safety of tepotinib challenge after capmatinib-induced pneumonitis in a patient with non-small cell lung cancer harboring MET exon 14 skipping mutation: a case report. Int. J. Mol. Sci. 23, 11809 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1469_CR228","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00277-018-3412-8","volume":"97","author":"I Fujioka","year":"2018","unstructured":"Fujioka, I. et al. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann. Hematol. 97, 2081\u20132088 (2018).","journal-title":"Ann. Hematol."},{"key":"1469_CR229","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12185-017-2225-1","volume":"106","author":"KJ Suh","year":"2017","unstructured":"Suh, K. J. et al. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. Int. J. Hematol. 106, 229\u2013239 (2017).","journal-title":"Int. J. Hematol."},{"key":"1469_CR230","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood.V122.21.257.257","volume":"122","author":"H Emir","year":"2013","unstructured":"Emir, H. et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy In CML. Blood 122, 257\u2013257 (2013).","journal-title":"Blood"},{"key":"1469_CR231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-015-0005-8","volume":"1","author":"O Pasvolsky","year":"2015","unstructured":"Pasvolsky, O. et al. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardio-Oncol. 1, 1\u201310 (2015).","journal-title":"Cardio-Oncol."},{"key":"1469_CR232","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani, A. et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 1, 643\u2013651 (2015).","journal-title":"JAMA Oncol."},{"key":"1469_CR233","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic, E. et al. Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site. Leukemia 31, 2388\u20132397 (2017).","journal-title":"Leukemia"},{"key":"1469_CR234","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1182\/blood.V122.21.1482.1482","volume":"122","author":"L Aprile","year":"2013","unstructured":"Aprile, L. et al. Atherothrombotic Risk and TKIs treatment in chronic myeloid leukemia patients: a role for genetic predisposition and pro-inflammatory\/pro-oxidative status? Blood 122, 1482\u20131482 (2013).","journal-title":"Blood"},{"key":"1469_CR235","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood.V126.23.2798.2798","volume":"126","author":"A Gover-Proaktor","year":"2015","unstructured":"Gover-Proaktor, A. et al. Pathogenesis of ponatinib associated vascular disease in chronic myeloid leukemia: an in vitro study. Blood 126, 2798\u20132798 (2015).","journal-title":"Blood"},{"key":"1469_CR236","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/leu.2014.342","volume":"29","author":"D Rea","year":"2015","unstructured":"Rea, D. et al. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia 29, 1206\u20131209 (2015).","journal-title":"Leukemia"},{"key":"1469_CR237","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1182\/blood.V122.21.4007.4007","volume":"122","author":"J Pinilla-Ibarz","year":"2013","unstructured":"Pinilla-Ibarz, J. et al. Clinical impact of dose modification on response to ponatinib in patients with chronic phase chronic myeloid leukemia (CP-CML). Blood 122, 4007\u20134007 (2013).","journal-title":"Blood"},{"key":"1469_CR238","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/ki.2011.288","volume":"80","author":"P Kandula","year":"2011","unstructured":"Kandula, P. & Agarwal, R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 80, 1271\u20131277 (2011).","journal-title":"Kidney Int."},{"key":"1469_CR239","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00280-017-3300-2","volume":"79","author":"C Teuma","year":"2017","unstructured":"Teuma, C. et al. Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury. Cancer Chemother. Pharmacol. 79, 1043\u20131049 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1469_CR240","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/cncr.28709","volume":"120","author":"V Launay-Vacher","year":"2014","unstructured":"Launay-Vacher, V. et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients. Cancer 120, 2158\u20132163 (2014).","journal-title":"Cancer"},{"key":"1469_CR241","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ckj\/sfv149","volume":"9","author":"R Wanchoo","year":"2016","unstructured":"Wanchoo, R., Jhaveri, K. D., Deray, G. & Launay-Vacher, V. Renal effects of BRAF inhibitors: A systematic review by the Cancer and the Kidney International Network. Clin. Kidney J. 9, 245\u2013251 (2016).","journal-title":"Clin. Kidney J."},{"key":"1469_CR242","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","volume":"1","author":"KD Jhaveri","year":"2015","unstructured":"Jhaveri, K. D., Sakhiya, V. & Fishbane, S. Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol. 1, 1133\u20131134 (2015).","journal-title":"JAMA Oncol."},{"key":"1469_CR243","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","volume":"158","author":"CH Choe","year":"2014","unstructured":"Choe, C. H., McArthur, G. A., Caro, I., Kempen, J. H. & Amaravadi, R. K. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am. J. Ophthalmol. 158, 831\u2013837.e2 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"1469_CR244","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers, S. et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117, 313 (2010).","journal-title":"Ophthalmology"},{"key":"1469_CR245","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","volume":"124","author":"JH Francis","year":"2017","unstructured":"Francis, J. H. et al. Clinical and morphologic characteristics of MEK inhibitor\u2013associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 124, 1788\u20131798 (2017).","journal-title":"Ophthalmology"},{"key":"1469_CR246","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/OPX.0000000000001833","volume":"99","author":"RT Claiborne","year":"2022","unstructured":"Claiborne, R. T. & Tsan, G. L. Case report: erdafitinib-induced central serous chorioretinopathy. Optom. Vis. Sci. 99, 88\u201392 (2022).","journal-title":"Optom. Vis. Sci."},{"key":"1469_CR247","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato, A. R. et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the united states: a real-world analysis. Haematologica 103, 874\u2013879 (2018).","journal-title":"Haematologica"},{"key":"1469_CR248","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ejh.13020","volume":"100","author":"BF Tillman","year":"2018","unstructured":"Tillman, B. F., Pauff, J. M., Satyanarayana, G., Talbott, M. & Warner, J. L. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur. J. Haematol. 100, 325\u2013334 (2018).","journal-title":"Eur. J. Haematol."},{"key":"1469_CR249","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky, J. A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122, 2539\u20132549 (2013).","journal-title":"Blood"},{"key":"1469_CR250","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.3324\/haematol.2014.119669","volume":"100","author":"M Borge","year":"2015","unstructured":"Borge, M. et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica 100, e140\u2013e142 (2015).","journal-title":"Haematologica"},{"key":"1469_CR251","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","volume":"132","author":"A Bercusson","year":"2018","unstructured":"Bercusson, A., Colley, T., Shah, A., Warris, A. & Armstrong-James, D. Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood 132, 1985\u20131988 (2018).","journal-title":"Blood"},{"key":"1469_CR252","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","volume":"4","author":"CE Ryan","year":"2020","unstructured":"Ryan, C. E., Cheng, M. P., Issa, N. C., Brown, J. R. & Davids, M. S. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv. 4, 1458\u20131463 (2020).","journal-title":"Blood Adv."},{"key":"1469_CR253","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens, D. M. & Byrd, J. C. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 133, 1298\u20131307 (2019).","journal-title":"Blood"},{"key":"1469_CR254","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","volume":"131","author":"JR Brown","year":"2018","unstructured":"Brown, J. R. How i treat CLL patients with ibrutinib. Blood 131, 379\u2013386 (2018).","journal-title":"Blood"},{"key":"1469_CR255","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1182\/blood-2019-121675","volume":"134","author":"C Pleyer","year":"2019","unstructured":"Pleyer, C. et al. Response to the Shingrix Varicella Zoster virus (VZV) vaccine in patients with chronic lymphocytic leukemia (CLL) that are treatment naive or treated with a Bruton\u2019s tyrosine kinase inhibitor (BTK-I). Blood 134, 3053\u20133053 (2019).","journal-title":"Blood"},{"key":"1469_CR256","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1111\/bcp.13933","volume":"85","author":"MM Fachi","year":"2019","unstructured":"Fachi, M. M. et al. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis. Br. J. Clin. Pharmacol. 85, 2280\u20132291 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1469_CR257","first-page":"95","volume":"8","author":"A Ostojic","year":"2012","unstructured":"Ostojic, A., Vrhovac, R. & Verstovsek, S. Ruxolitinib for the treatment of myelofibrosis: Its clinical potential. Ther. Clin. Risk. Manag. 8, 95\u2013103 (2012).","journal-title":"Ther. Clin. Risk. Manag."},{"key":"1469_CR258","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","volume":"100","author":"A Galanis","year":"2015","unstructured":"Galanis, A. & Levis, M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica 100, e77 (2015).","journal-title":"Haematologica"},{"key":"1469_CR259","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","volume":"39","author":"C Sillaber","year":"2009","unstructured":"Sillaber, C. et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140\u2003mg daily. Eur. J. Clin. Invest. 39, 1098\u20131109 (2009).","journal-title":"Eur. J. Clin. Invest."},{"key":"1469_CR260","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/TCRM.S1527","volume":"4","author":"M Henkes","year":"2008","unstructured":"Henkes, M., van der Kuip, H. & Aulitzky, W. E. Therapeutic options for chronic myeloid leukemia: Focus on imatinib (Glivec\u00ae, GleevecTM). Ther. Clin. Risk. Manag. 4, 163\u2013187 (2008).","journal-title":"Ther. Clin. Risk. Manag."},{"key":"1469_CR261","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","volume":"114","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama, A., Han, X., Kantarjian, H. & Cortes, J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114, 261\u2013263 (2009).","journal-title":"Blood"},{"key":"1469_CR262","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1182\/blood-2009-02-205328","volume":"114","author":"MP Gratacap","year":"2009","unstructured":"Gratacap, M. P. et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 114, 1884\u20131892 (2009).","journal-title":"Blood"},{"key":"1469_CR263","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1188\/09.CJON.329-335","volume":"13","author":"I Galinsky","year":"2009","unstructured":"Galinsky, I. & Buchanan, S. Practical management of dasatinib for maximum patient benefit. Clin. J. Oncol. Nurs. 13, 329\u2013335 (2009).","journal-title":"Clin. J. Oncol. Nurs."},{"key":"1469_CR264","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1002\/cncr.24432","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama, A. et al. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 115, 3935\u20133943 (2009).","journal-title":"Cancer"},{"key":"1469_CR265","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","volume":"18","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien, S. et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma. Clin. Lymphoma Myeloma Leuk. 18, 648\u2013657.e15 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1469_CR266","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman, J. P. et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395, 1278\u20131291 (2020).","journal-title":"Lancet"},{"key":"1469_CR267","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","volume":"3","author":"G Dobie","year":"2019","unstructured":"Dobie, G. et al. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans. Blood Adv. 3, 4298\u20134311 (2019).","journal-title":"Blood Adv."},{"key":"1469_CR268","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.thromres.2020.05.012","volume":"192","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. & Diamond, S. L. Src family kinases inhibition by dasatinib blocks initial and subsequent platelet deposition on collagen under flow, but lacks efficacy with thrombin generation. Thromb. Res. 192, 141\u2013151 (2020).","journal-title":"Thromb. Res."},{"key":"1469_CR269","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3904\/kjim.2015.325","volume":"33","author":"E Yim","year":"2018","unstructured":"Yim, E., Choi, Y. G., Nam, Y. J., Lee, J. & Kim, J. A. Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia. Korean J. Intern. Med. 33, 446\u2013448 (2018).","journal-title":"Korean J. Intern. Med."},{"key":"1469_CR270","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1182\/blood-2010-12-326850","volume":"117","author":"A Mazharian","year":"2011","unstructured":"Mazharian, A., Ghevaert, C., Zhang, L., Massberg, S. & Watson, S. P. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 117, 5198\u20135206 (2011).","journal-title":"Blood"},{"key":"1469_CR271","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/bjh.15690","volume":"184","author":"JR Brown","year":"2019","unstructured":"Brown, J. R. et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br. J. Haematol. 184, 558\u2013569 (2019).","journal-title":"Br. J. Haematol."},{"key":"1469_CR272","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.14660","volume":"178","author":"JA Jones","year":"2017","unstructured":"Jones, J. A. et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single\u2010agent ibrutinib. Br. J. Haematol. 178, 286 (2017).","journal-title":"Br. J. Haematol."},{"key":"1469_CR273","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel, J. J. et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J. Thromb. Haemost. 15, 835\u2013847 (2017).","journal-title":"J. Thromb. Haemost."},{"key":"1469_CR274","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/blood.2018884940","volume":"135","author":"JC Byrd","year":"2020","unstructured":"Byrd, J. C. et al. Acalabrutinib monotherapy in patients with relapsed\/ refractory chronic lymphocytic leukemia: Updated phase 2 results. Blood 135, 1204\u20131213 (2020).","journal-title":"Blood"},{"key":"1469_CR275","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/sj.leu.2404025","volume":"20","author":"PR Pilot","year":"2006","unstructured":"Pilot, P. R., Sablinska, K., Owen, S. & Hatfield, A. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 20, 148 (2006).","journal-title":"Leukemia"},{"key":"1469_CR276","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","volume":"118","author":"D Verma","year":"2011","unstructured":"Verma, D. et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118, 4353\u20134358 (2011).","journal-title":"Blood"},{"key":"1469_CR277","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3109\/10428194.2013.806805","volume":"55","author":"E Togasaki-Yoshimoto","year":"2014","unstructured":"Togasaki-Yoshimoto, E., Shono, K., Onoda, M. & Yokota, A. The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia. Leuk. Lymphoma 55, 453\u2013456 (2014).","journal-title":"Leuk. Lymphoma"},{"key":"1469_CR278","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1634\/theoncologist.2019-0109","volume":"24","author":"X Dou","year":"2019","unstructured":"Dou, X., Qin, Y., Huang, X. & Jiang, Q. Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Oncologist 24, e1141\u2013e1147 (2019).","journal-title":"Oncologist"},{"key":"1469_CR279","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(07)70242-5","volume":"8","author":"AA Robinson","year":"2007","unstructured":"Robinson, A. A., Watson, W. J. & Leslie, K. K. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol. 8, 738\u2013743 (2007).","journal-title":"Lancet Oncol."},{"key":"1469_CR280","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s10815-021-02181-6","volume":"38","author":"A Rambhatla","year":"2021","unstructured":"Rambhatla, A., Strug, M. R., De Paredes, J. G., Cordoba Munoz, M. I. & Thakur, M. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. J. Assist. Reprod. Genet. 38, 1897\u20131908 (2021).","journal-title":"J. Assist. Reprod. Genet."},{"key":"1469_CR281","doi-asserted-by":"publisher","first-page":"2014028","DOI":"10.4084\/mjhid.2014.028","volume":"6","author":"E Abruzzese","year":"2014","unstructured":"Abruzzese, E., Trawinska, M. M., Perrotti, A. P. & De Fabritiis, P. Tyrosine kinase inhibitors and pregnancy. Mediterr. J. Hematol. Infect. Dis. 6, 2014028 (2014).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"1469_CR282","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","volume":"36","author":"A Granatowicz","year":"2015","unstructured":"Granatowicz, A. et al. An overview and update of chronic myeloid leukemia for primary care physicians. Korean J. Fam. Med. 36, 197\u2013202 (2015).","journal-title":"Korean J. Fam. Med."},{"key":"1469_CR283","doi-asserted-by":"publisher","first-page":"756672","DOI":"10.3389\/fonc.2021.756672","volume":"11","author":"S Deng","year":"2021","unstructured":"Deng, S., Solinas, A. & Calvisi, D. F. Cabozantinib for HCC treatment, from clinical back to experimental models. Front. Oncol. 11, 756672 (2021).","journal-title":"Front. Oncol."},{"key":"1469_CR284","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","volume":"94","author":"J Hakkola","year":"2020","unstructured":"Hakkola, J., Hukkanen, J., Turpeinen, M. & Pelkonen, O. Inhibition and induction of CYP enzymes in humans: an update. Arch. Toxicol. 94, 3671\u20133722 (2020).","journal-title":"Arch. Toxicol."},{"key":"1469_CR285","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3109\/00498254.2015.1109160","volume":"46","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. Xenobiotica 46, 651\u2013658 (2016).","journal-title":"Xenobiotica"},{"key":"1469_CR286","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/liv.12524","volume":"35","author":"QF Xiang","year":"2015","unstructured":"Xiang, Q. F. et al. Cabozantinib reverses multidrug resistance of human hepatoma HepG2\/adr cells by modulating the function of P-glycoprotein. Liver Int. 35, 1010\u20131023 (2015).","journal-title":"Liver Int."},{"key":"1469_CR287","doi-asserted-by":"publisher","first-page":"8875","DOI":"10.3390\/ijms23168875","volume":"23","author":"V Barresi","year":"2022","unstructured":"Barresi, V., Musmeci, C., Rinaldi, A. & Condorelli, D. F. Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets. Int. J. Mol. Sci. 23, 8875 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1469_CR288","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.3390\/ijms23052736","volume":"23","author":"H Zogg","year":"2022","unstructured":"Zogg, H., Singh, R. & Ro, S. Current advances in RNA therapeutics for human diseases. Int. J. Mol. Sci. 23, 2736 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1469_CR289","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor, M. H. et al. Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J. Clin. Oncol. 38, 1154 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1469_CR290","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.2147\/CMAR.S216605","volume":"12","author":"V Chau","year":"2020","unstructured":"Chau, V. & Bilusic, M. Pembrolizumab in combination with axitinib as first-line treatment for patients with renal cell carcinoma (RCC): evidence to date. Cancer Manag. Res. 12, 7321 (2020).","journal-title":"Cancer Manag. Res."},{"key":"1469_CR291","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1469_CR292","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas, A., Teicher, B. A. & Hassan, R. Antibody\u2013drug conjugates for cancer therapy. Lancet Oncol. 17, e254\u2013e262 (2016).","journal-title":"Lancet Oncol."},{"key":"1469_CR293","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","volume":"235","author":"S Yaghoubi","year":"2020","unstructured":"Yaghoubi, S. et al. Potential drugs used in the antibody\u2013drug conjugate (ADC) architecture for cancer therapy. J. Cell. Physiol. 235, 31\u201364 (2020).","journal-title":"J. Cell. Physiol."},{"key":"1469_CR294","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/molecules27031075","volume":"27","author":"BG de la Torre","year":"2022","unstructured":"de la Torre, B. G. & Albericio, F. The pharmaceutical industry in 2021. An analysis of FDA drug approvals from the perspective of molecules. Molecules 27, 1075 (2022).","journal-title":"Molecules"},{"key":"1469_CR295","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi, J. J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375, 1457\u20131467 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1469_CR296","doi-asserted-by":"crossref","unstructured":"Kalash, R. S., Lakshmanan, V. K., Cho, C. S. & Park, I. K. Theranostics. Biomaterials Nanoarchitectonics. 197\u2013215 (William Andrew Publishing, 2016).","DOI":"10.1016\/B978-0-323-37127-8.00012-1"},{"key":"1469_CR297","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.3390\/ijms22126538","volume":"22","author":"E Russo","year":"2021","unstructured":"Russo, E., Spallarossa, A., Tasso, B., Villa, C. & Brullo, C. Nanotechnology of tyrosine kinase inhibitors in cancer therapy: A perspective. Int. J. Mol. Sci. 22, 6538 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1469_CR298","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1038\/onc.2014.291","volume":"34","author":"W Du","year":"2015","unstructured":"Du, W. & Elemento, O. Cancer systems biology: Embracing complexity to develop better anticancer therapeutic strategies. Oncogene 34, 3215\u20133225 (2015).","journal-title":"Oncogene"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01469-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T20:02:51Z","timestamp":1688673771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01469-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":298,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01469-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}